XTLB (XTL Biopharmaceuticals) ROC %: -144.95% (As of Jun. 2025)

What is XTL Biopharmaceuticals ROC %?

XTL Biopharmaceuticals XTLB -8.01% 24 ROC % is -144.95% as of Jun. 2025. GuruFocus rates XTLB with a GF Score™ of 24/100. The stock has 2 warning signs investors should review.

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. XTL Biopharmaceuticals's annualized return on capital (ROC %) for the quarter that ended in Jun. 2025 was -144.95%.

As of today (2026-06-26), XTL Biopharmaceuticals's WACC % is 8.63%. XTL Biopharmaceuticals's ROC % is -146.37% (calculated using TTM income statement data). XTL Biopharmaceuticals earns returns that do not match up to its cost of capital. It will destroy value as it grows.

XTL Biopharmaceuticals (NAS:XTLB) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, XTL Biopharmaceuticals's WACC % is 8.63%. XTL Biopharmaceuticals's ROC % is -146.37% (calculated using TTM income statement data). XTL Biopharmaceuticals earns returns that do not match up to its cost of capital. It will destroy value as it grows.

Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

XTL Biopharmaceuticals ROC % Related Terms

XTL Biopharmaceuticals ROC % Historical Data

* Premium members only.

The historical data trend for XTL Biopharmaceuticals's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

XTL Biopharmaceuticals ROC % Chart

XTL Biopharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

ROC %

Get a 7-Day Free Trial

-240.00

-270.25

-231.27

-201.32

-42.47

XTL Biopharmaceuticals Semi-Annual Data
	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24	Jun25
ROC %	Get a 7-Day Free Trial															-217.89	-184.74	-232.13	-58.11	-144.95

24GF Score

XTL Biopharmaceuticals Ltd XTLB

ROC % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

XTL Biopharmaceuticals ROC % Calculation

XTL Biopharmaceuticals's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2024 is calculated as:

	ROC % (A: Dec. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (A: Dec. 2023 )	+	Invested Capital (A: Dec. 2024 ))	/ count )
=	-2.172 * ( 1 - 11.24% )	/	( (0.38	+	8.698)	/ 2 )
=	-1.9278672	/	4.539
=	-42.47 %

where

	Invested Capital		(A: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	2.426	-	0.206	-	( 2.006	-	max(0, 0.206	-	2.046	+	2.006	))
=	0.38

	Invested Capital		(A: Dec. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	8.55	-	0.719	-	( 1.143	-	max(0, 2.207	-	1.34	+	1.143	))
=	8.698

XTL Biopharmaceuticals's annualized Return on Capital (ROC %) for the quarter that ended in Jun. 2025 is calculated as:

	ROC % (Q: Jun. 2025 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2024 )	+	Invested Capital (Q: Jun. 2025 ))	/ count )
=	-6.784 * ( 1 - 3.83% )	/	( (8.698	+	0.304)	/ 2 )
=	-6.5241728	/	4.501
=	-144.95 %

where

	Invested Capital		(Q: Dec. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	8.55	-	0.719	-	( 1.143	-	max(0, 2.207	-	1.34	+	1.143	))
=	8.698

	Invested Capital		(Q: Jun. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0.714	-	0.638	-	( 0.259	-	max(0, 0.761	-	0.533	+	0.259	))
=	0.304

Note: The Operating Income data used here is two times the semi-annual (Jun. 2025) data. The tax rate is limited to between 0% and 100%.

Frequently Asked Questions Learn more about ROC % →

What does a ROC % of -144.95% mean?

XTL Biopharmaceuticals (XTLB) has a ROC % of -144.95% as of Jun. 2025. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on XTL Biopharmaceuticals and its competitors.

Is XTL Biopharmaceuticals' ROC % too high?

XTL Biopharmaceuticals' current ROC % is -144.95%. Overall, XTL Biopharmaceuticals has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.

How does XTL Biopharmaceuticals' ROC % compare to VRTX and REGN?

XTL Biopharmaceuticals' ROC % of -144.95% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROC % for a Biotechnology company?

A good ROC % depends on the Biotechnology industry context. However, ROC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROC % mean?

A high ROC % can signal that a stock is expensive relative to its fundamentals. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on XTL Biopharmaceuticals and its competitors. XTL Biopharmaceuticals's current ROC % is -144.95%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is XTL Biopharmaceuticals stock overvalued right now?

XTL Biopharmaceuticals (XTLB) has a current ROC % of -144.95%. The current ROC % is -144.95%. XTL Biopharmaceuticals' overall GF Score™ is 24/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROC % calculated?

ROC % is calculated from a company's financial statements. For XTL Biopharmaceuticals (XTLB), the current ROC % is -144.95% as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

XTL Biopharmaceuticals Business Description

Industry Healthcare Biotechnology

Comparable Companies XTAE:PPBT XTAE:CANF XTAE:EVGN XTAE:HDST-M XTAE:BOLT XTAE:BLRX XTAE:CBI VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270 RPRX BNTX INSM

Other Exchanges XTLB:Israel HHB0:Germany

Address 26 Ben-Gurion Street, Ramat Gan, ISR, 5112001

Website https://www.xtlbio.com

XTL Biopharmaceuticals Ltd is engaged in the development of therapeutics for the treatment of unmet medical needs. Its products include hCDR1 and Recombinant Human Erythropoietin (rHuEPO). hCDR1 is a Phase II-ready asset compound, working through a mechanism of action, for the treatment of Systemic Lupus Erythematosus (SLE) and Sjogren's syndrome. hCDR1 is a synthetic peptide that includes approximately 20 amino-acid residues. rHuEPO, a known agent for anemia, is being developed to prolong the survival of patients with multiple myeloma (MM). rHuEPO is used in clinical practice for the treatment of various anemias, including anemia of kidney disease and cancer-related anemia.

24GF Score

Get the complete analysis for XTLB

ROC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.57

Price

View XTLB Analysis

See ROC % data for all stocks →